Dose reduction versus dose-interval prolongation in eribulin mesilate monotherapy in patients with metastatic breast cancer: A retrospective comparative study.

Dose reduction versus dose-interval prolongation in eribulin mesilate monotherapy in patients with metastatic breast cancer: A retrospective comparative study. Yakugaku Zasshi. 2016 Mar 31; Authors: Sasaki T, Oshima Y, Mishima E, Ban A, Katsuragawa K, Nagamatsu H, Yoshioka Y, Tsukiyama I, Hisada T, Itakura Y, Mizutani M Abstract <bibitem lang="en"> It is often necessary to modify the dose or schedule of Eri (eribulin mesilate) because of adverse events. Therefore, we retrospectively investigated the optimal approach for Eri dose adjustment and/or dosage interval adjustment. Patients who received Eri at the institutions affiliated with the Division of Oncology of the Aichi Prefectural Society of Hospital Pharmacists between July 2011 and November 2013 were enrolled in this study. We compared the group that underwent dose reduction without changes to their dosage interval (dose reduction group) with the group that had a change in their dosage interval (dose-interval prolongation group). The primary end-point was TTF (time to treatment failure), and the secondary end-points were OS (overall survival), ORR (overall response rate), CBR (clinical benefit rate), and adverse events. The TTF and OS of the dose reduction group were approximately two times longer than those of the dose-interval prolongation group. In addition, the dose reduction group had significantly improved ORR and CBR, which together indicate an antitumor effect ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research